miR196b-/-Dnmt3a+/-Flt3ITD mice also develop AML with significantly shorter latency compared to Dnmt3a+/–Flt3ITD control mice with median survivals of 33 days and 41 days, respectively (Fig. 1B-C). Here, DNMT3A is linked to acute myeloid leukemia.